Summary:
- The article discusses the findings of a survey by Lazard, a financial advisory firm, which indicates an expected uptick in bolt-on M&A (mergers and acquisitions) and broader use of artificial intelligence (AI) in the biotech and pharmaceutical industries.
- The survey suggests that companies are increasingly looking to acquire smaller, specialized firms to expand their capabilities and product pipelines, rather than pursuing larger, transformative deals.
- Additionally, the article highlights the growing adoption of AI technologies in the life sciences sector, with companies leveraging these tools for drug discovery, clinical trial optimization, and other applications.